最多等待 10 秒，若超时请稍后重试。
Ziyu Kuang, Jingyuan Wu, Ying Tan, Guanghui Zhu, Jie Li, Min Wu
Oncology Department, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China.
Graduate School, Beijing University of Chinese Medicine, Beijing 100029, China.
Biomolecules. 2023 Mar 20;13(3):568. doi: 10.3390/biom13030568.
Doxorubicin (DOX), a broad-spectrum chemotherapy drug, is widely applied to the treatment of cancer; however, DOX-induced cardiotoxicity (DIC) limits its clinical therapeutic utility. However, it is difficult to monitor and detect DIC at an early stage using conventional detection methods. Thus, sensitive, accurate, and specific methods of diagnosis and treatment are important in clinical practice. MicroRNAs (miRNAs) belong to non-coding RNAs (ncRNAs) and are stable and easy to detect. Moreover, miRNAs are expected to become biomarkers and therapeutic targets for DIC; thus, there are currently many studies focusing on the role of miRNAs in DIC. In this review, we list the prominent studies on the diagnosis and treatment of miRNAs in DIC, explore the feasibility and difficulties of using miRNAs as diagnostic biomarkers and therapeutic targets, and provide recommendations for future research.
多柔比星（DOX）是一种广谱化疗药物，广泛应用于癌症治疗；然而，多柔比星诱导的心脏毒性（DIC）限制了其临床治疗用途。然而，传统的检测方法很难在早期监测和检测 DIC。因此，在临床实践中，敏感、准确和特异的诊断和治疗方法很重要。微小 RNA（miRNA）属于非编码 RNA（ncRNA），稳定且易于检测。此外，miRNA 有望成为 DIC 的生物标志物和治疗靶点；因此，目前有许多研究集中在 miRNA 在 DIC 中的作用。在这篇综述中，我们列出了 miRNA 在 DIC 诊断和治疗方面的突出研究，探讨了将 miRNA 用作诊断生物标志物和治疗靶点的可行性和困难，并为未来的研究提供了建议。
